ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Multiple Myeloma

Multiple Myeloma

A new study found that monitoring of minimal residual disease in a group of elderly patients with multiple myeloma proved to have important prognostic value, regardless of patient age or cytogenetic risk.

Continuous lenalidomide plus low-dose dexamethasone reduced the risk for progression in untreated multiple myeloma patients who were ineligible for stem cell transplantation.

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

CD38 expression was associated with response to daratumumab monotherapy in patients with multiple myeloma.

Researchers were able to identify a subset of patients with smoldering multiple myeloma who have a greater than 80% risk of progressing to myeloma within 2 years.

Monotherapy with the monoclonal antibody isatuximab was effective and well-tolerated in a small study of patients with relapsed and refractory multiple myeloma.

In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.